Form 4: Clover Health CEO's Future Tax-Related Stock Sale

Clover Health CEO Conrad Wai filed a Form 4 detailing a future disposition of 98,412 shares for tax obligations from RSU vesting on September 14, 2025.

Summary

• Conrad Wai, CEO of Counterpart Health and an officer of Clover Health Investments, Corp. (CLOV), reported a planned disposition of 98,412 shares of Class A Common Stock.
• The disposition is scheduled for September 14, 2025, and is intended to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs).
• The shares will be disposed of at a price of $3.06 per share.
• This transaction represents the withholding of shares upon the vesting of 6.25% of the original time-based RSUs granted to Mr. Wai on March 14, 2022.
• Following this planned transaction, Mr. Wai will directly beneficially own 1,573,425 shares of Class A Common Stock.
• Additionally, 1,403,701 shares are indirectly beneficially owned through a trust for the benefit of his family, where Mr. Wai serves as a co-trustee.
• Remaining RSUs are scheduled to vest quarterly in equal installments of 6.25%, with a final vesting date on March 14, 2026, contingent on Mr. Wai's continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-scheduled insider transaction related to executive compensation (RSU vesting and tax withholding), which is generally considered neutral in its immediate impact on company fundamentals or stock price.

Positives

• The scheduled vesting of Restricted Stock Units (RSUs) on September 14, 2025, represents a planned compensation event for the executive, indicating continued retention and alignment with company performance.

Negatives

• The planned disposition of 98,412 shares, valued at $3.06 per share, will reduce the executive's direct beneficial ownership of Class A Common Stock.

Future Outlook

The filing indicates a future RSU vesting event on September 14, 2025, with subsequent quarterly vesting installments until a final vesting date of March 14, 2026, all contingent on the reporting person's continued service.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation-related transaction for an executive.
• Employees: No direct impact mentioned.
• Executive (Conrad Wai): Receives vested equity compensation, with a portion sold to cover tax liabilities, maintaining a significant beneficial ownership stake.

Next Steps

• Future quarterly vesting of remaining RSUs in equal installments of 6.25% until March 14, 2026, subject to Conrad Wai's continued service.

Key Dates

Recommendation

This Form 4 details a routine, pre-scheduled insider transaction involving the disposition of shares to cover tax obligations upon RSU vesting. Such events are common for executives and typically do not provide new information that would warrant a change in investment thesis or stock recommendation. The transaction is an expected part of executive compensation and does not reflect a discretionary sale based on new company performance insights.

Keywords

Clover Health, CLOV, Conrad Wai, Form 4, SEC filing, stock sale, RSU vesting, tax withholding, insider transaction, executive compensation